Profile data is unavailable for this security.
About the company
GenMont Biotech Incorporation is a Taiwan-based company principally engaged in the manufacture and distribution of functional lactobacillus. The Company's major products include lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus fermentum, lactobacillus salivarius, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus brevis, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus johnsonii and others. The Company’s products are applied to enhance human immunity against dust allergy and digestive system health care. The Company distributes its products in domestic market and to overseas markets.
- Revenue in TWD (TTM)391.48m
- Net income in TWD34.49m
- Incorporated2000
- Employees147.00
- LocationGenMont Biotech IncNo.8, Tainan Science-Based Industrl PrkNan-Ke 7th RoadShanhua DistrictTAINAN 741TaiwanTWN
- Phone+886 65052151
- Fax+886 65052152
- Websitehttps://www.genmont.com.tw/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GenMont Biotech Inc | 391.48m | 34.49m | 1.53bn | 147.00 | 44.45 | 1.19 | 16.38 | 3.90 | 0.3993 | 0.3993 | 4.52 | 14.86 | 0.2405 | 1.88 | 11.78 | -- | 1.57 | 3.46 | 1.82 | 4.12 | 60.23 | 66.89 | 6.51 | 15.75 | 4.12 | 4.74 | 0.0707 | 102.22 | 21.18 | 2.16 | 73.54 | -0.0697 | -35.41 | -0.2454 |
| Hunya Foods Co Ltd | 1.93bn | -25.20m | 2.28bn | 1.09k | -- | 0.909 | 10.54 | 1.18 | -0.2908 | -0.2908 | 22.32 | 28.93 | 0.5032 | 5.19 | 6.31 | -- | -0.6555 | 2.21 | -0.7579 | 2.72 | 26.22 | 26.95 | -1.30 | 4.13 | 0.9616 | -3.43 | 0.2475 | 75.28 | 2.48 | 1.18 | -253.45 | -- | 95.47 | 9.86 |
Data as of Feb 11 2026. Currency figures normalised to GenMont Biotech Inc's reporting currency: Taiwan Dollar TWD
0.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 125.31k | 0.15% |
| DFA Australia Ltd.as of 30 Nov 2025 | 382.00 | 0.00% |
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
